Angiotensin Converting Enzyme 2 News and Research

RSS

SARS-CoV-2 Omicron BA.2 differs antigenically from previous variants

Researchers observed that the SARS-CoV-2 Omicron BA.2 variant is immunologically different from other variants, including Omicron BA.1.

16 May 2022

Super-antibody UT28K shows broad-spectrum activity against SARS-CoV-2 variants

A study, published online in the journal mAbs, describes a novel mAb, UT28K, that has promising broadly neutralizing activity against the SARS-CoV-2 virus.

15 May 2022

Artificial proteins as specific and versatile neutralizing binders targeting the spike of SARS-CoV-2

Researchers demonstrated that the biosynthetic proteins called αReps addressing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein could be novel SARS-CoV-2 antivirals

13 May 2022

Researchers identify compounds from Aspergillus that may be effective against SARS-CoV-2

Researchers from Ain Shams University have been exploring the use of compounds isolated from Aspergillus sp. against SARS-CoV-2.

13 May 2022

Development of a novel surface plasmon resonance-based assay to determine kinetics of SARS-CoV-2 spike – human ACE2 interaction

A team of scientists has recently studied the kinetic and thermodynamic characteristics of interaction between human ACE2 and spike receptor-binding domains of different variants of SARS-CoV-2.

13 May 2022

SARS-CoV-2 N-terminal domain modulates S1/S2 cleavage and spike-mediated functions

In a recent study posted to the bioRxiv* preprint server, researchers explored the role of the N-terminal domain (NTD) of the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) spike (S) protein in SARS-CoV-2 fusion with the host membranes and coronavirus disease 2019 (COVID-19).

12 May 2022

Bayesian viral allele selection for SARS-CoV-2 genomic surveillance

In a recent study posted to the bioRxiv* preprint server, researchers assessed the selection effects in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using Bayesian viral allele selection.

12 May 2022

Delta- and Omicron BA.1-variant specificity of B cell repertoires established by an initial Wuhan strain infection

Researchers performed an unbiased evaluation of the early memory B cell repertoire specific for the Omicron and Delta variants of SARS-CoV-2.

12 May 2022

Imprinted antibody responses towards SARS-CoV-2 Omicron subvariants

A new study analyzed the imprinted antibody responses towards the SARS-CoV-2 Omicron subvariants.

12 May 2022

SARS-CoV-2 Omicron escapes immune response due to high ACE2 affinity and low antibody specificity

In a recent study published in the journal Vaccines, researchers revealed how severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron evades neutralizing antibodies (nAbs).

12 May 2022

Antifungal agent Bifonazole as an antiviral against SARS-CoV-2

In a recent study published in the journal Molecular Therapy, researchers identified Bifonazole, an imidazole-based antifungal agent, to have potent activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using high-throughput screening of small molecules.

12 May 2022

Discovery of host co-factors necessary for SARS-CoV2 infection

A new study published in the journal EMBO Reports has reported on the shedding of two proteases, namely, ADAM10 and ADAM17, which aids in S protein-dependent molecular events.

11 May 2022

Decoy ACE2 nanoparticles block the entry of SARS-CoV-2 into cells

In a recent study posted to the bioRxiv* preprint server, researchers reported that nanoparticles could prevent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) cell entry.

10 May 2022

Exploring simultaneous and sequential COVID-19 vaccine candidate

Researchers developed novel lipid nanoparticle (LNP)-based messenger ribonucleic acid vaccine formulations against three pathogenic coronaviruses.

10 May 2022

Evasion of COVID-19 vaccine-medicated mucosal immunity by SARS-CoV-2 Omicron

Researchers depicted the evasion of the SARS-CoV-2 Omicron variant to mucosal immunity in SARS-CoV-2 vaccine recipients.

10 May 2022

Simulating molecular dynamics of SARS-CoV-2 spike variants in the locked conformation

Researchers retrieved the first-ever sequenced spike (S) protein structures of the original Wuhan-Hu 1 SARS-CoV-2 strain, the Alpha, Delta, Delta-plus variants, and Omicron sub-variants BA.1 and BA.2 and compared their structural and molecular level variations.

10 May 2022

Research highlight reports on the observed differences in transmissibility and pathogenicity of Omicron vs. earlier variants of SARS-CoV-2

A new paper published in Signal Transduction and Targeted Therapy reports the observed differences in transmissibility and pathogenicity of Omicron vs. earlier variants of SARS-CoV-2.

10 May 2022

mRNA boosters enhance neutralization of SARS-CoV-2 BA.1, BA.2 and BA.3

A study recently published in the journal Cell Host & Microbe has described that all three sublineages of the omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit similar host cell entry efficiency and are neutralized equally by antibodies generated in response to coronavirus disease 2019 (COVID-19) booster vaccination

10 May 2022

Personalized text messaging program improves healthy lifestyle measures in heart attack survivors

A text messaging program successfully supported, informed and motivated people after a heart attack on how to prevent a second heart attack, according to new research published today in the American Heart Association's flagship, peer-reviewed journal Circulation.

9 May 2022

Differences in COVID-19 outcomes related to sex

Researchers looked at gender variations in COVID-19 outcomes such as hospitalization, ICU admission, mortality, and heart damage.

9 May 2022

Angiotensin Converting Enzyme 2 News and Research

SARS-CoV-2 Omicron BA.2 differs antigenically from previous variants

Super-antibody UT28K shows broad-spectrum activity against SARS-CoV-2 variants

Artificial proteins as specific and versatile neutralizing binders targeting the spike of SARS-CoV-2

Researchers identify compounds from Aspergillus that may be effective against SARS-CoV-2

Development of a novel surface plasmon resonance-based assay to determine kinetics of SARS-CoV-2 spike – human ACE2 interaction

SARS-CoV-2 N-terminal domain modulates S1/S2 cleavage and spike-mediated functions

Bayesian viral allele selection for SARS-CoV-2 genomic surveillance

Delta- and Omicron BA.1-variant specificity of B cell repertoires established by an initial Wuhan strain infection

Imprinted antibody responses towards SARS-CoV-2 Omicron subvariants

SARS-CoV-2 Omicron escapes immune response due to high ACE2 affinity and low antibody specificity

Antifungal agent Bifonazole as an antiviral against SARS-CoV-2

Discovery of host co-factors necessary for SARS-CoV2 infection

Decoy ACE2 nanoparticles block the entry of SARS-CoV-2 into cells

Exploring simultaneous and sequential COVID-19 vaccine candidate

Evasion of COVID-19 vaccine-medicated mucosal immunity by SARS-CoV-2 Omicron

Simulating molecular dynamics of SARS-CoV-2 spike variants in the locked conformation

Research highlight reports on the observed differences in transmissibility and pathogenicity of Omicron vs. earlier variants of SARS-CoV-2

mRNA boosters enhance neutralization of SARS-CoV-2 BA.1, BA.2 and BA.3

Personalized text messaging program improves healthy lifestyle measures in heart attack survivors

Differences in COVID-19 outcomes related to sex

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News